Lupin receives Form 483 with 4 observations from USFDA for Pithampur unit-2

The company is addressing these observations comprehensively

Shilpa Medicare receives EIR from USFDA for Unit VI, Bengaluru

This facility is capable of manufacturing, packaging, testing, storage and distribution of two types of complex dosage forms

Briefs: Emcure Pharmaceuticals and Gland Pharma

Emcure Pharmaceuticals successfully completes USFDA PAI of Oncology facility

Azelis acquires Azienda Chimica e Farmaceutica to expand presence in Italy

Azelis will strengthen its presence in the domestic market by leveraging portfolio synergies, actively consolidating the business, and creating value for all stakeholders

Shilpa Pharma Lifesciences Unit-1 inspected by ANVISA

The audit has been concluded with no major observations

WuXi XDC announces mechanical completion of Singapore site

The site, spanning approximately 25,000 square meters, is expected to commence operations by the end of 2025

SMS Pharmaceuticals completes USFDA inspection at Central Laboratory Analytical Services

The inspection concluded with zero Form 483 observations

Covestro launches localized production of medical-grade TPU in Asia Pacific

Changhua site meets international regulatory standards for global medical applications

Sanner commences manufacturing critical injection-molded components in USA

The GMP-compliant facility with automated environmental monitoring accommodates both white room and class 7 and 8 cleanroom space

USFDA concludes inspection at Zydus' oncology injectable plant at Ahmedabad